# Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

> **NCT01324232** · PHASE2 · COMPLETED · sponsor: **Avanir Pharmaceuticals** · enrollment: 209 (actual)

## Conditions studied

- Central Neuropathic Pain
- Multiple Sclerosis

## Interventions

- **DRUG:** AVP-923-45
- **DRUG:** AVP-923-30
- **DRUG:** AVP-923-20
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01324232
- **Lead sponsor:** Avanir Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-08
- **Primary completion:** 2013-09-26
- **Final completion:** 2013-09-26
- **Target enrollment:** 209 (ACTUAL)
- **Last updated:** 2021-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01324232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01324232, "Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01324232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*